Overview

An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease

Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy. Patient safety and quality of life will also be monitored throughout the study.
Phase:
Phase 3
Details
Lead Sponsor:
Tillotts Pharma AG